Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Inovio Pharmaceuticals Stock Jumped Today

By Cory Renauer – Updated Apr 6, 2020 at 3:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company started a clinical trial with its potential new COVID-19 vaccine.

What happened

Shares of Inovio Pharmaceuticals (INO -8.70%), a clinical-stage biopharmaceutical, jumped on Monday after the company initiated a clinical trial with an experimental COVID-19 vaccine. Hopeful investors drove the stock 9.2% higher as of 3:07 p.m. EST on Monday.

So what 

Today, the Food and Drug Administration accepted Inovio's application to run clinical trials with INO-4800, an experimental DNA vaccine designed to prevent transmission of SARS-CoV-2, the virus responsible for COVID-19. The green light from the agency allows Inovio to begin a phase 1 clinical trial that will enroll up to 40 healthy volunteers.

Stethoscope and a rising stock chart.

Image source: Getty Images.

Investors were impressed with Inovio's ability to rapidly get a vaccine ready for clinical-stage testing, a process that generally takes more than a year. The genetic sequence of the virus, which informed the initial development of INO-4800, didn't become available until early this January.

Now what

Beginning today, trial volunteers will begin receiving their first dose of INO-4800 to be followed by a second and final dose four weeks later. That means initial immune responses and safety data could be ready by late summer.

Inovio is one of the best companies in biotech at quickly advancing experimental vaccines into early clinical-stage testing. Unfortunately, the company doesn't have an encouraging track record past this point along the drug development timeline. Inovio has been developing medicines since 1983 but still doesn't have a single product to sell.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.68 (-8.70%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.